AbbVie Inc (ABBV)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 10,360,000 | 17,254,000 | 15,408,000 | 13,076,000 | -8,172,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | — |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $10,360,000K
= 0.00
The debt-to-equity ratio of Abbvie Inc has been fluctuating over the past five years, indicating varying levels of leverage and financial risk. In 2023, the ratio increased to 5.73 from 3.67 in 2022, suggesting a higher proportion of debt relative to equity in the company's capital structure. This increase could signify an aggressive financing strategy or recent borrowing activities to fund expansion or operations. Comparing to 2021 and 2020, where the ratio was 4.98 and 6.58 respectively, the current ratio of 5.73 falls within this range, indicating that Abbvie's debt levels are significant but have not reached the peak seen in 2020. The absence of data for 2019 makes it difficult to track the trend continuously, yet it can be noted that the company has historically maintained a relatively high debt-to-equity ratio, reflecting a reliance on debt financing. Further analysis of the company's overall financial health, industry comparables, and future debt management strategies would provide additional insight into the implications of this ratio for Abbvie Inc.
Peer comparison
Dec 31, 2023